tirzepatide risk It's important to study the difference in GLP-1 medications.⁣ Our analysis found is associated with a lower of serious heart and kidney complications compared to dulaglutide in adults with Type How Tirzepatide Supports Cardiovascular Health

Our 2025 study in JMIR Formative Research examined 12-month outcomes for participants using semaglutide with behavioural support and found 1 : 19.1% average weight loss at 12 months for active subscribers 77.7% achieved at least 10% weight loss 61.5% achieved at least 15% weight loss 69% reported no side effects by month 12 These are completer results (people who stayed on the programme for 12 months), not intent-to-treat

Weight loss during the first week of semaglutide is typically modestusually 1 to 3 poundsand reflects changes in appetite, fluid retention, and initial metabolic adjustment rather than significant fat loss

Average body fat (20-30% for men, 25-35% for women) Most needle lengths work well

Start by talking to your doctor or a sleep specialist about the risks and benefits of taking a GLP-1 agonist for OSA

Clinical trials demonstrate average weight loss of 15-22% with tirzepatide compared to 10-15% with semaglutide, though individual responses vary considerably